SANTA CLARA, Calif.--(BUSINESS WIRE)--November 03, 2026--
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, November 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2026. Management will be providing updates on recent achievements, including the ALIGN-ACS pilot study results, as well as upcoming milestones for the Heart Attack Detection program. A press release detailing the third quarter results will be issued prior to the call.
HeartBeam Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, Ph.D., and Chief Financial Officer Timothy Cruickshank will host the conference call, followed by a question-and-answer period.
The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed following the call via the investor relations section of the Company's website here.
To access the call, please use the following information:
Date: Thursday, November 12, 2026
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-in: 1-877-704-4453
International Dial-in: 1-201-389-0920
Conference Code: 13763268
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1779198&
tp_key=0e699c3be5
A telephone replay will be available approximately three hours after the call and will run through November 26, 2026, by dialing 1-844-512-2921 from the U.S. and Canada, or 1-412-317-6671 from international locations, and entering replay pin number: 13763268. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company's investor relations section here.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care -- all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025(1) . The technology is currently being studied for heart attack assessment and is considered investigational in that indication. The Company holds over 25 issued patents related to technology enablement. For additional information, visit HeartBeam.com.
(1) Cleared Indications for Use
The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment only. The technology's use for heart attack assessment is investigational and not FDA cleared. For full details on the intended use of the HeartBeam technology, refer to the Company's Cleared Indications for Use and full instructions at https://www.heartbeam.com/indications.
MKT-173 v0
View source version on businesswire.com: https://www.businesswire.com/news/home/20261103699541/en/
CONTACT: Media Contact:
media@heartbeam.com
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Comments